Note 15- Collaborative and Other Relationships (Details Textual) $ in Thousands								1 Months Ended		12 Months Ended			70 Months Ended
	Sep. 15, 2021 USD ($)	Sep. 01, 2021 USD ($)	Mar. 04, 2020 USD ($)	Nov. 05, 2019 USD ($)	Sep. 06, 2018 USD ($)	Jun. 16, 2015 USD ($)	Sep. 30, 2013 USD ($)	Aug. 31, 2020 USD ($)	Jun. 30, 2000 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Mar. 31, 2021 USD ($)	Mar. 31, 2015 USD ($)
Revenue from Contract with Customer, Including Assessed Tax										$ 157,170	$ 17,812	$ 48,835
Arbitration Proceedings of SUL Agreement [Member]
Litigation Settlement, Amount Awarded from Other Party			$ 5,000
Arbitration Proceedings of SUL Agreement [Member] | Other Income [Member]
Gain (Loss) Related to Litigation Settlement, Total											8,893
Arbitration Proceedings of SUL Agreement [Member] | Selling, General and Administrative Expenses [Member]
Legal Fees											5,026
US Department of Health and Human Services [Member]
Collaborative Agreement Contract Value					$ 34,660
Contract Term (Year)					5 years
US Department of Health and Human Services [Member] | RAPIVAB [Member]
Maximum Number of Products, Doses					50,000
Number of Product Delivered, Doses										9,980		20,000
Proceeds from Collaborators										$ 6,918		$ 13,900
Number of Additional Products, Doses		10,000
Revenue from Contract with Customer, Including Assessed Tax		$ 6,900
Torii Pharmaceutical Co. [Member]
Revenue from Contract with Customer, Including Assessed Tax				$ 22,000
Potential Milestone Payments Receivable if Regulatory Approval Before December 31, 2021				$ 15,000
Maximum Customary Reduction on Royalty Rate				50.00%
Royalty Payments Receivable, Expiration Term From First Commercial (Year)				10 years
Contract with Customer, Liability, Revenue Recognized											$ 1,899	$ 20,101
Torii Pharmaceutical Co. [Member] | Minimum [Member]
Royalty Rate if Maintains Sakigake Designation				20.00%
Torii Pharmaceutical Co. [Member] | Maximum [Member]
Royalty Rate if Maintains Sakigake Designation				40.00%
CSL Limited [Member
Proceeds from License Fees Received						$ 33,740
Milestone Payment Received													$ 12,000
Base Contract [Member]
Government Contract Receivable														$ 16,265
Additional Development Options [Member]
Government Contract Receivable														22,855
ASPRBARDA Contract [Member]
Government Contract Receivable														$ 39,120
Proceeds from awards for Research and Development Contracts										$ 20,574
AECOM and IRL [Member]
Milestone Payment Minimum									$ 1,400
Milestone Payment Maximum									4,000
Annual License Fee Minimum									150
Annual License Fee Maximum									$ 500
National Institute of Allergy and Infectious Diseases [Member]
Expected Receivable From Awards for Research and Development Contracts	$ 47,315						$ 45,931
Collaborative Agreement Contract, Covenant, Maximum Amount of Funding								$ 43,908
Collaborative Agreement Contract Value								$ 6,326
UAB [Member]
Period of Agreement (Year)										25 years
Renewable Period of Agreement (Year)										5 years